Webcast

The Role of Antibody Drug Conjugates in Advanced Non-Small Cell Lung Cancer: Guidance for Today and the Path Forward

Launch Date
12/01/2020
Credit Amount
0.00 Expired
Credit Expires
12/01/2021

Faculty

Hossein Borghaei, DO, MS
Chief, Division of Thoracic Medical Oncology
Professor, Department of Hematology/Oncology
Gloria and Edmund M. Dunn Chair in Thoracic Oncology, Fox Chase Cancer Center
Temple Health, Philadelphia, PA
Hossein Borghaei, DO, MS
Chief, Division of Thoracic Medical Oncology

Dr. Borghaei earned his degree at Philadelphia College of Osteopathic Medicine and completed a residency at Graduate Hospital in Philadelphia. Since completing his fellowship training at Fox Chase Cancer Center, he has been involved in a number of clinical trials aimed at developing new, antibody-based therapies and immunotherapies for patients with lung cancer.

In addition to his clinical practice and participation in immunotherapy-based clinical trials, Dr. Borghaei is the principal investigator (PI) of a laboratory that develops new monoclonal antibodies and novel immune-modulating drugs, with the aim of bringing these approaches to the clinic. He served as the PI of a phase III randomized study that proved the effectiveness of nivolumab in the treatment of patients with advanced non-squamous non-small cell lung cancer after progression on prior chemotherapy. This work led to the approval of nivolumab, one of the first immunotherapy-based drugs to be approved for lung cancer in this setting.

Dr. Borghaei is a member of the thoracic core committee at Eastern Cooperative Oncology Group (ECOG) and, until recently, was a member of the National Comprehensive Cancer Network (NCCN) Non-Small Cell Lung Cancer panel. He is the recipient of an American Society of Clinical Oncology (ASCO) Young Investigator Award and an ASCO Career Development Award. Dr. Borghaei is a long-standing member of ASCO, AACR, IASLC, and SITC as well as the ECOG thoracic committee.

Dr. Borghaei has been a recipient of the Robert Krigel Memorial Award for Teaching Excellence from Fox Chase Cancer Center, ASCO’s Young Investigator Award, and the Career Development Award from ASCO. His work has been published in The New England Journal of Medicine, Journal of Clinical Oncology, The Lancet Oncology, Leukemia Research, Journal of Thoracic Oncology, Clinical Cancer Research, Clinical Lung Cancer, and Journal of the National Comprehensive Cancer Network.

Enriqueta Felip, MD, PhD
Section in Chief, Medical Oncology Department
Head, Thoracic and Head and Neck Oncology Unit
Associate Professor of Medicine (UCC), Barcelona, Spain
Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology
Enriqueta Felip, MD, PhD

Enriqueta Felip is the Head of the Thoracic Cancer Unit within the Oncology Department of Vall d’Hebron Hospital, Barcelona, Spain. Professor Felip is in charge of thoracic malignancy management and is responsible for thoracic cancer trials undertaken by the Oncology Department. Dr. Felip received her medical degree from the Autonomous University of Barcelona (UAB), where she also completed her PhD studies in medical oncology. She has been Associate Professor at UAB from 2010 to May 2019. She is involved in the training of medical students, residents, and particularly in mentoring fellows.

Dr. Felip is currently a member of the Spanish Lung Cancer Group (SLCG) and the Spanish Society of Medical Oncology (SEOM). In October 2019, she was elected SEOM Vice-President for 2019-2021.

Dr. Felip is also member of the European Society of Medical Oncology (ESMO), the American Society of Clinical Oncology (ASCO), and the International Association for the Study of Lung Cancer (IASLC). She is a member of the Board of Directors of IASLC (2017-2021).

Dr. Felip has been involved in several initiatives with scientific organizations, among them, as Subject Editor of Guidelines Working group ESMO Minimum Clinical Recommendations in lung cancer and Coordinator of the 1st ESMO Consensus Conference in lung cancer. She is at present a member of the scientific committee of the SLCG.

Dr. Felip is also author of many peer-reviewed articles and book chapters relating to the field of thoracic malignancies.

The magnitude of Dr. Felip’s contribution to the biomedical sciences is remarkable as she is one of the most cited authors in 2018 and 2019: Global Highly Cited Researcher list 2018 (Source: Clarivate Analytics).

David E. Gerber, MD
Professor of Internal Medicine and Population & Data Sciences, University of Texas Southwestern Medical Center
Associate Director of Clinical Research, Co-Leader of the Experimental Therapeutics Scientific Program, Harold C. Simmons Comprehensive Cancer Center at UT Southwestern, Dallas, TX
David E. Gerber, MD

Dr. Gerber is Professor of Internal Medicine and Population & Data Sciences at UT Southwestern Medical Center. Within the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern, Dr. Gerber serves as Associate Director of Clinical Research and as Co-Leader of the Experimental Therapeutics Scientific Program.

Explore By Section
Statement of Need Learning Objectives Financial Support Target Audience Credit Information Disclosure Declaration Additional Formats

Statement of Need

The discovery of molecular alterations that drive tumor initiation and progression has revolutionized the treatment strategy for non-small cell lung cancer (NSCLC) by matching targeted therapies to a specific mutation, leading to significantly improved therapeutic efficacy. However, despite the initial effectiveness of targeted therapy for NSCLC, most patients ultimately develop acquired resistance with subsequent disease progression, making it imperative for clinicians to receive up-to-date education on evaluating new therapeutic options to improve outcomes and better tailor treatment strategies.

In this CME Outfitters Live and OnDemand, integrations of animated 3-D models will provide visual representation of the mechanisms and characteristics of antibody drug conjugates (ADCs) in NSCLC to complement expert faculty insights and evidence supporting testing strategies to identify predictive biomarkers, emerging treatment options for advanced or metastatic NSCLC, and best practices for managing patients with lung cancer in the face of COVID-19 and beyond.

Learning Objectives

At the end of this CME/CE activity, participants should be able to:

  • Apply molecular testing to identify predictive biomarkers for targeted therapy in advanced NSCLC.
  • Evaluate the rationale for emerging therapies in advanced or metastatic NSCLC
  • Employ best practices to manage lung cancer during the COVID-19 pandemic.

The following learning objectives pertain only to those requesting CNE or CPE credit:

  • Summarize how molecular testing can identify predictive biomarkers for targeted therapy in advanced NSCLC.
  • Evaluate the rationale for emerging therapies in advanced or metastatic NSCLC.
  • Describe best practices to manage lung cancer during the COVID-19 pandemic.

Financial Support

Supported by an educational grant from Daiichi Sankyo, Inc.

Target Audience

Hematology/oncology specialists, surgeons, pathologists, nurse practitioners, PAs, nurses, and pharmacists.

Credit Information

Physicians (ACCME) 1.0

CME Outfitters, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Note to Nurse Practitioners

Nurse Practitioners can apply for AMA PRA Category 1 Credit ™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit ™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

Pharmacists/Pharmacy Tech (ACPE) 1.0

This application-based activity is approved for 1.0 contact hour (0.10 CEUs) of continuing pharmacy credit.

ABIM MOC 1.0

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Borghaei reports he receives research support from Bristol-Myers Squibb Company/Eli Lilly and Company and Merck & Co./Celgene Corporation. He is on the advisory committee for AbbVie Inc.; Amgen Inc.; AstraZeneca; Axiom Healthcare Services; BioNTech; Boehringer Ingelheim; Bristol-Myers Squibb Company; Cantargia AB; Celgene Corporation; Daiichi Sankyo, Inc.; Eli Lilly and Company; EMD Serono, Inc.; Genentech, Inc.; Genmab; GLG; HUYA Bioscience International; Merck & Co.; Novartis; Pfizer Inc.; PharmaMar; Regeneron Pharmaceuticals Inc.; and Takeda Pharmaceuticals U.S.A., Inc. He is a consultant for Amgen; AstraZeneca; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; EMD Serono, Inc.; and PharmaMar. He receives other financial or material support from Data and Safety Monitoring Board: Incyte; Takeda Pharmaceuticals U.S.A., Inc. and University of Pennsylvania. He is on the scientific advisory board for Rgenix (stock options) and Sonnet BioTherapeutics, Inc. (stock options).

Dr. Felip reports she receives research funding from Fundación Merck Salud and a grant for Oncology Innovation (GOI) EMD Serono. She serves in a advisory role or speakers bureau for for AbbVie Inc.; Amgen Inc.; Astra Zeneca, Bayer, Blueprint Medicines Corporation; Boehringer Ingelheim; Bristol-Myers Squibb Company; Eli Lilly and Company; F. Hoffmann-La Roche; GlaxoSmithKline; Janssen Global Services; Merck KGaA; Merck Sharp & Dohme Corp.; Novartis; Pfizer Inc.: Puma Biotechnology, Inc.; Sanofi Genzyme, Springer; and Takeda Pharmaceutical Company. She recieves other financial or material support from Grifols (independent board member).

Dr. Geber reports he receives research support from AstraZeneca; BerGenBio; Bristol-Myers Squibb Company; and Karyopharm. He is a consultant for Bristol-Myers Squibb Company; Catalyst Pharmaceuticals, Inc.; G1 Therapeutics, Inc.; Karyopharm; and Samsung Bioepis. He is a stock shareholder (directly purchased) in Gilead Sciences, Inc.

Poshala Tish Aluwihare, PhD (planning committee) has no disclosures to report.

Howard Bliwise, MD (peer reviewer) has no disclosures to report.

Mae Ochoa, RPh (peer reviewer) has no disclosures to report.

Susan Perry (planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Additional Formats

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.

 

NOTE: Pharmacist CE Universal Activity Number, Enduring: 0376-0000-20-148-H01-P.

Questions about this activity?

Call us at (877) CME-PROS or (877) 263-7767.

 

TV-121-120120-65

The Role of Antibody Drug Conjugates in Advanced Non-Small Cell Lung Cancer: Guidance for Today and the Path Forward
Event Date: 12/01/2020